Survival after regional perfusion for limb melanoma.
Regional perfusion has been carried out in the limbs of a group of patients with recurrent melanoma, and has achieved disappearance of visible disease in the affected limb in 10 patients out of 28 (36%), prevention of local recurrence in five, and no effect on the disease in nine. This control of recurrent melanoma cost no mortality, but did carry a definite but acceptable morbidity.
D000671:Amputation, Surgical; D010478:Chemotherapy, Cancer, Regional Perfusion; D005121:Extremities; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality*; D012737:Sex Factors; D012878:Skin Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use
D013852:Thiotepa; D008558:Melphalan